ESTRO Multidisciplinary Management of Breast Cancer 2017

Risk factors for cardiotoxicity

-Increased cumulative dose -Age -Predisposition cardiac disease -Meidastinal irradiation -Hormonal therapy -Risk factors cardiovasc. disease

Risk of developing congestive heart failure over 2.5 years after epirubicin treatment

Ryberg M et al, JNCI 2008

19-9-2017